Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Shire to resubmit dry-eye disease drug to FDA with new study data

London-listed pharma firm Shire said its dry-eye disease drug lifitegrast significantly improved patient symptoms in a new study, supporting a re-submission of the potentially block-busting medicine to U.S. regulators early next year. Shares in Shire jumped more than 6 percent after it announced the positive results of the study on Tuesday. They were trading up […]

Read More »

GSK heart drug flops in study, shingles vaccine on track

An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines.   Losmapimod was being assessed as a treatment to reduce the risk of further cardiovascular problems after heart attacks, but it […]

Read More »

Amgen, Cytokinetics heart failure drug succeeds in mid-stage study

Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study. The 448 patients in the trial were given an oral formulation of the drug omecamtiv mecarbil for 20 weeks and observed for 24 weeks, the companies […]

Read More »

Bio Blast Pharma reports promising data on muscle wasting drug

Bio Blast Pharma Ltd said its lead experimental drug showed signs of being effective in treating patients with a rare muscle wasting disorder, besides also hitting the main goals of safety and tolerability. The company said the experimental drug, Cabaletta, hit multiple efficacy endpoints during a mid-stage trial on patients suffering from oculopharyngeal muscular dystrophy, […]

Read More »

Novartis AG to Cough Up $390 Million to Settle U.S. Kickback Case

Novartis AG agreed to pay $390 million to resolve a lawsuit claiming the company paid kickbacks to increase sales of several prescription drugs. The agreement is preliminary. The payment covers all claims related to the medicines Myfortic, Exjade, Tasigna, Gleevec and TOBI, the company said. The U.S. had sought as much as $3.3 billion from […]

Read More »

Bacon and other processed meats can cause cancer, experts say

Eating processed meats like hot dogs, sausages and bacon can cause colorectal cancer in humans, and red meat is also a likely cause of the disease, World Health Organization (WHO) experts said. The review by WHO’s International Agency for Research on Cancer (IARC), released on Monday, said additionally that there was some link between the […]

Read More »

Cancer diagnosis brings income loss for families

(Reuters Health) – The average U.S. adult diagnosed with cancer will miss five weeks of work in the first year and see total family income decline by 20 percent, according to a new study. Those numbers may be even higher for some, as they average the experiences of people with various types and stages of […]

Read More »

FDA sees no heart risks from Novartis’ Parkinson’s drug

U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required […]

Read More »

Merck’s Keytruda extends survival in lung cancer study

Merck & Co’s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease. The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking […]

Read More »

MERS, Ebola, bird flu: Science’s big missed opportunities

Anyone who goes down with flu in Europe this winter could be asked to enroll in a randomized clinical trial in which they will either be given a drug, which may or may not work, or standard advice to take bed rest and paracetamol. Those who agree could be helping the world prepare for the […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom